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U sin g  site -d ire cte d  m u tag e n esis, w e  p ro p o sed  th a t an  
a u to in h ib ito ry  d om ain (s) is lo cated  a t  th e  C -term in al 
re g io n  (3 0 1 - 3 8 6 ) o f  th e p h o sp h o ry la se  k in a se  y-su b u n it 
(H u an g, C .-Y . F ., Y u a n , C .-J ., L iv a n o v a , N . B ., a n d  G ra v e s, 
D . J .  (1 9 9 3 ) M ol. C e ll. B io c h e m .  1 27/1 2 8 , 7 - 1 8 ). R em o va l o f  
th e  p u ta tiv e  in h ib ito ry  dom ain (s) b y  tru n ca tio n  re su lts  
in  th e  g e n e ra tio n  o f  a  c o n stitu tiv e ly  a c tiv e  a n d  calm o d ­
u lin -in d e p en d e n t fo rm , y ^ o o - T o  p ro b e  th e stru c tu ra l  
b a s is  o f  a u to in h ib itio n  o f  y-su b u n it a c tiv ity , tw o  sy n ­
th e tic  p ep tid e s, P h K 13  ^303-327) an d  P h K 5  (y343_367)»cor_ 
re sp o n d in g  to th e  tw o  ca lm o d u lin -b in d in g  re g io n s, w e re  
a s sa y e d  fo r  th e ir  a b ility  to  in h ib it y ^ o o - C o m p etitive  
in h ib itio n  o f yi_3oo b y  P h K 13  w a s  fo u n d  v e r s u s  p h o sp h o ­
ry la s e  b  CK; =  1 .8  /uM) a n d  n o n co m p e titive  in h ib itio n  
v e r s u s  A T P . P h K 5  sh o w e d  n o n co m p e titive  in h ib itio n  
w ith  re sp e ct to b o th  p h o sp h o ry la se  b  a n d  A T P . C alm o d ­
u lin  re le a se d  th e  in h ib itio n  ca u se d  b y  bo th  p ep tid es. 
T h e se  re su lts  in d ic a te  th a t th e re  a re  tw o  d istin ct au to ­
in h ib ito ry  d o m ain s w ith in  th e  C  te rm in u s o f th e  y-su b ­
u n it a n d  th a t th e se  tw o  d o m ain s o v e rla p  w ith  th e  c a l­
m o d u lin -b in d in g  re g io n s. T w o  m u tan t fo rm s o f y^ o o *  
E 111K  a n d  E 1 5 4 R , w e re  u sed  to p ro b e th e  en zym e-su b ­
s tra te -b in d in g  re g io n  u s in g  p ep tid e  su b stra te  an alo gs  
c o rre sp o n d in g  to re sid u e s 9 - 1 8  o f  p h o sp h o ry la se  b 
(K R K 11Q 12I S V R G L ). T h e  d a ta  su g g e st th a t G lu 111 in te r­
a c ts  w ith  th e  P -3  p o sitio n  o f  th e  su b stra te  (L y s 1 1 ) an d  
G lu 154 in te ra c ts  w ith  th e  P -2  site  (G in 12). B o th  E 111 K  
a n d  E 1 5 4 R  w e re  c o m p e titive ly  in h ib ited  w ith  re sp e ct to  
p h o sp h o ry la se  b  b y  P h K 1 3 , w ith  14 - a n d  8 -fold h ig h e r K t 
va lu e s, re sp e ctiv e ly , th a n  th a t o b se rv e d  w ith  th e w ild ­
ty p e  en zym e. T h e se  d a ta  a re  co n sisten t w ith  a  m odel fo r  
th e  re g u la tio n  o f  th e  y-su b u n it o f  p h o sp h o ry la se  k in ase  
in  w h ic h  P h K 13  a c ts  as  a  co m p etitive  p se u d o su b strate  
th a t d ire c tly  b in d s th e  su b stra te  b in d in g  site  o f  the  
y-su b u n it (G lu 111 a n d  G lu 154).
Phosphorylase kinase catalyzes the phosphorylation and ac­
tivation of glycogen phosphorylase b (for review see Refs. 1 and 
2). Phosphorylase kinase has a subunit composition in white 
skeletal muscle of (a,j3,y,8)4. The a- and 0-subunits are regu­
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latory subunits. The 8-subunit is almost identical to bovine 
brain calmodulin and confers Ca2+ sensitivity upon the en­
zyme. The y-subunit is catalytically active, and its N-terminal 
region (residues 1-276) shares sequence homology with the 
catalytic domains of other protein kinases (3). The C-terminal 
region of y (residues 287-386) is thought to encompass two 
distinct, non-contiguous high affinity calmodulin-binding sub­
domains (4). This speculation is supported by the results that 
exogenous calmodulin can stimulate the y-subunit isolated 
from rabbit skeletal muscle (5, 6) as well as the recombinant 
full-length y forms (7-12), but not the truncated y forms (11,
13, 14).
Several calmodulin-dependent protein kinases, e.g. myosin 
light chain kinase and Ca2' /calmodulin-dependent protein ki­
nase II, have been shown to contain an autoinhibitory domain 
or a pseudosubstrate sequence in their primary structures, 
which partly overlaps with their respective calmodulin-binding 
regions (reviewed in Refs. 15 and 16). In both instances, cal­
modulin plays an important role in releasing the inhibition 
imposed by the inhibitory domain. Because the autoinhibitory 
domain in calmodulin-dependent protein kinases usually over­
laps with their calmodulin-binding domain, two calmodulin- 
binding peptides, PhK13 (7303-327) ar>d PhK5 (y343_367)» from 
the C terminus of the 7-subunit are potential models for study­
ing autoinhibitory mechanisms in the y-subunit. We have em­
ployed a simple system, the truncated constitutively active 7, 
7i_300, and the two synthetic peptides, PhK13 and PhK5, to 
investigate the possibility that those two regions of the 7-sub­
unit regulatory domain might act as autoinhibitory domains. 
Two mutants of 71_300, E111K and E154R, which have been 
reported previously to have altered substrate binding affinity
(18), were also used in this study to define substrate/ 
pseudosubstrate binding sites in the catalytic domain of the 
y-subunit.
EXPERIMENTAL PROCEDURES
Materials—[y-32P]ATP was purchased from ICN Biomedicals. Other 
reagents were purchased from Sigma. Phosphorylase b was prepared 
from rabbit skeletal muscle as described in Ref. 19. PhK13 (GKFKVI- 
CLTVLASVRIYYQYRRVKP), a peptide sequence derived from the cal­
modulin-binding domain y303_327; PhosO-18)1 peptide, corresponding 
to the phosphorylatable region (residues 9—18) of phosphorylase b; and 
analogs of Phos(9-18) peptides, E10, E ll ,  and E12, were synthesized in 
the Protein Facility at Iowa State University and purified by reverse- 
phase high performance liquid chromatography with a C-18 column. 
PhK5 (LRRLIDAYAFRIYGHWVKKGQQQNR), corresponding to the 
calmodulin-binding domain y343_367, was synthesized at the University 
of Utah and purified as described previously (4).
Expression and Purification o f M utant '/■Subunits—Expression and 
purification of 7 . :i0« and its mutant forms, E111K and E154R, were 
done by using the T7 RNA polymerase-based expression system (20) as
1 The abbreviations used are: Phos(9-18) peptide, KRKQISVRGL; 
E10 peptide, KEKQISVRGL; E l l  peptide, KREQISVRGL; E12 peptide, 
















7184 Autoinhibition of Phosphorylase Kinase y-Subunit
T a b le  I
K, values and kinetic mechanisms for the inhibition o f y, :100 and its m utant forms 
Data were obtained using non-linear curve-fitting procedures and linear secondary plots as described under “Experimental Procedures.” Values 
are means ± S.D. from a t least three different experiments. Phos. b, phosphorylase b.
71—300 forms Inhibitors Substrates Inhibition Ki Kn
JAM JAM
Wild-type PhK13 Phos. b Competitive 1.8 ± 0.1
Wild-type PhK13 ATP Noncompetitive 30.9 ± 1.5 29.8 ± 1.3
Wild-type PhK5 Phos. b Noncompetitive 62.2 ± 3.0 63.1 ± 3.5
Wild-type PhK5 ATP N oncompetitive 119 ± 4 116 ± 3
E111K PhK5 Phos. b Noncompetitive 67.2 ± 2.1 67.7 ± 2.2
E154R PhK5 Phos. b Noncompetitive 10 1  ± 6 106 ± 4
E111K PhK13 Phos. b Competitive 25.8 ± 1.3
E111K PhK13 ATP N oncompetitive 91.9 ± 4.6 90.0 ± 4.5
E154R PhK13 Phos. b Competitive 15.0 ± 1.2
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F ig . 1. Comparison of the inhibition of -y1_soo by PhK13 and 
PhK5 . The final concentrations in the assay were 50 mM Tris, pH 8.2, 
50 mM HEPES, 10 mM MgCl2, 4 jam phosphorylase b, 1 mM dithiothre­
itol, 1 mM [7-32P]-ATP, 1 jAg/ml 7130o> and various concentrations of 
PhK13 {panel A) or PhK5 (panel B). The reaction was carried out at 
30 °C for 5 min.
described previously (11). All of the recombinant proteins were purified 
to homogeneity as judged by SDS-gel electrophoresis (data not shown).
Protein and Peptide Concentration Determination—Protein concen­
trations were determined by the Bradford assay with commercially 
prepared reagents from Bio-Rad (21). Peptide solutions were prepared 
based on their dry weight.
Activity Assay—The protein kinase activity of the 7-subunit was 
determined by incorporation of 32P into phosphorylase b as described 
previously with some modification (5, 22). The standard assay was 
performed at 30 °C for 5 min and contained final concentrations of 60 
mM Tris, pH 8.2, 60 mM HEPES, 10 mM MgCl2, 100 jam phosphorylase 
b, 1 mM dithiothreitol, 1 mM [7-32P]ATP, and 0.1-2 jig/ml •y1_30o (wild- 
type and mutant forms) in the reaction mixture. In the inhibition assays 
(Figs. 1 and 2), the standard assay was used except PhK13 or PhK5 
were added and the final concentrations of phosphorylase b and y^oo 
were adjusted to 4 jam and 1 /xg/ml, respectively. The calmodulin (or 
BSA) activation assay was done as follows. The standard assay mixture 
as described above containing PhK13 (10 jam) or PhK5 (250 jam) was 
first incubated a t 30 °C for 5 min. Then, an equimolar concentration (10 
jam or 250 jam) of calmodulin (or BSA) was added and incubated for 
another 10 min a t 30 °C. Reactions were stopped by spotting on ET-31 
filter paper (Whatman) and by processing the filters as described by 
Reimann et al. (23). The radioactivity incorporated was determined by 
liquid scintillation counting.
In the kinetic analyses, the concentration ranges of substrate (ATP 
and phosphorylase b) were varied from 1/2 K m to 5 times K m. With 
wild-type yi_30o> studies were done using (a) varying concentrations of 
phosphorylase b (10—90 jam) and inhibitor peptides (0—7.2 jam for PhK13 
and 0-51 jam for PhK5) a t a fixed concentration of ATP (400 jam), and (6) 
varying concentrations of ATP (40—400 jxm) and inhibitor peptides 
(0-54 jam for PhK13 and 0-51 jam for PhK5) at a fixed concentration of 
phosphorylase b (90 /xM). The K m values for phosphorylase b using the 
E111K and E154R mutants of y^oo were both around 100 jam, but due
to insolubility it was impossible to obtain a final concentration of 500 
j a m  phosphorylase b (5 times K m). Therefore, a concentration of 225 ja m  
phosphorylase b was used as the greatest concentration in the E111K 
and E154R mutant assay. In the case of the kinetic analyses using 
Phos(9-18) peptide and Phos(9-18) peptide analogs (Table II) as sub­
strates, the concentration ranges of these peptides were varied from 0.5 
to 15 mM.
Kinetic data were analyzed with the program, Enzfitter (Elsevier 
Science Publishers). The initial velocity data (Table II) were fitted to the 
equation for a two-substrate random Bi Bi mechanism. The inhibition 
data (Table I) with PhK13 and PhK5 were fitted to the equations for 
competitive or noncompetitive inhibition with the program Enzfitter. 
The inhibition constants, K t for competitive inhibition and Kt and Ku for 
noncompetitive inhibition, were calculated from the linear secondary 
plots as illustrated in Fig. 3 (A  and B). All the kinetic analyses were 
repeated at least three times.
RESULTS
Effects ofPhK13 and PhK5 on -y;_.300—To determine whether 
PhK13 and PhK5 could act as possible inhibitory domains, 
these peptides were tested for their ability to inhibit the con­
stitutively active 7 , 7 1_300. The results showed that both pep­
tides could inhibit the kinase activity of y^oo- As shown in Fig. 
1, PhK13 is a more potent inhibitor (IC50 = 3 jam) than PhK5 
(IC50 = 80 jam). The inhibitory effects of both PhK13 and PhK5 
were largely reversed by adding equimolar concentrations of 
calmodulin (Fig. 2). Another protein, BSA, had little effect on 
the inhibitory effects of PhK13 and PhK5. This result suggests 
that calmodulin is specifically required to prevent the inhibi­
tory effect of PhK13 and PhK5.
Kinetic Analyses of the Inhibition of y , ;i00 by PhK13 and 
PhKS—Kinetic analyses were undertaken to determine the 
mechanism of the inhibitory properties of PhK13 and PhK5 on 
71-300- The results of these analyses showed that PhK13 is a 
competitive inhibitor of phosphorylase b phosphorylation and a 
noncompetitive inhibitor of ATP (Table I and Fig. 3). In con­
trast, PhK5 is a noncompetitive inhibitor of phosphorylase b 
and ATP. These results indicate the binding of PhK5 to the 
enzyme is not affected by the binding of substrate phosphoryl­
ase b. No further attempt was made to locate the possible 
binding site of PhK5 in 7^300 because noncompetitive inhibi­
tion with respect to both substrates indicates PhK5 may be 
binding at a site other than the ATP and phosphorylase b 
binding sites.
Identification of the Specificity Determinants of Phosphoryl­
ase b—To gain further insight regarding the inhibitory mech­
anism, we first mapped substrate binding sites between 7x_300 
and peptide substrate. This information was then used to eval­
uate where PhK13 binds and inhibits. Phos(9-18) peptide, 
K9RKQISVRGL18, containing the phosphorylation site, Ser14, 
of phosphorylase b, has been used as an alternative substrate 























Fig. 2. Inhibition of y1_3oo activity 
by PhK13 or PhK5 . The inhibition assay 
was performed as described under “Ex­
perimental Procedures.” The final concen­
trations of PhK13 or PhK5 were 10 and 
250 jj,m , respectively, and those of the 
o ther components were the same as 
described in Fig. 1. In the calmodulin 
(or BSA) activation assay, equimolar 
amounts (10 or 250 /<.M) of calmodulin (or 
BSA) relative to PhK13 or PhK5 were 
used in the reaction mixture. The assay 
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F ig . 3. Initial velocity patterns for 
inhibition of y1JOO by PhK13 (A) and 
PhK5 (B). Activity was assayed as de­
scribed under “Experimental Proce­
dures.” The final concentrations of pep­
tides in the assay were PhK13 (0, 2.7, 4.5, 
and 7.2 /xM) and PhK5 (0, 17, 34, and 51 
/xM). K t and Ku were estimated from the 
linear secondary plots (insets in A and B).
1 1 [Phos. b] (mM)
25). Previously, Graves and co-workers (26, 27) demonstrated ognition N-terminal to Ser14 (P site). To test whether y,_300 has 
that Lys11 (P-3 site) and Gin12 (P-2 site) of the Phos(9-18) the same substrate specificity determinants as phosphorylase 















7186 Autoinhibition of Phosphorylase Kinase y-Subunit
Table II
Efficiency o f 9-18, E10, E l l ,  and E12 peptides as substrates o f wild-type y1_30o aRd  its charge-reversal m utan t forms, E111K and E154R  








Enzyme Substrate K m Vr max Relativeefficiency^
mM nmol P J  m in  I nmol enzyme
Wild-type 9-18 0.9 ± 0.1 1400 ± 300 1.0
E10 0.9 ± 0.1 1600 ± 150 1.1
E l l 9.0 ± 0.6 1500 ± 200 0 .11
E12 2.9 ±  0.4 1300 ± 90 0.29
E154R 9-18 4.1 ± 0.3 690 ± 150 0 .11
E l l 4.1 ± 0.3 470 ± 80 0.074
E12 1.5 ± 0.3 740 ± 40 0.32
E111K 9-18 5.0 ± 0.5 10 ± 1 0.0013
E l l 1.5 ± 0.02 110 ± 3 0.047
E12 4.6 ± 0.5 12 ± 1 0.0017
9 - 1 8 :  9K - R - K -Q - I -S - V - R - G -L 1 
E 1 0 : K -E -K -Q —I -S - V -R -G -L  
E l l :  K -R -E -Q —I -S - V -R -G -L  
E 1 2 : K -R -K -E —I -S - V -R -G -L
° Relative efficiency was calculated as: (Vmax/iTm)peptide/(VmJ K n l , a, where (Vmax//fm)peptide represents the VmJ K m ratio of the peptide being 
tested and (VmalI/Km)9_18 represents the VmaJK m ratio of the wild-type 7 1_:HOo enzyme using phosphoryl (9-18) peptide as substrate.
prepared by replacing Arg10, Lys11, and Gin12 with glutamyl. 
These peptide analogs were termed E10, E l l ,  and E12, respec­
tively (Table II). Phos(9-18) and its glutamyl-substituted pep­
tides were individually tested as substrates of y^oo to evaluate 
the effects on substrate recognition by yi_30o-2 Table II compares 
the results of these kinetic analyses and relative enzymatic effi­
ciency (VmA ) peptldi/(VmJ 4 ) p h „ ^ i 8r Peptide E10 showed 
little change in relative enzymatic efficiency (1 10 %), indicating 
Arg10 in Phos(9-18) is not essential for y^ oo  recognition. Lower 
relative enzymatic efficiencies were found in E l l  (11%) and E12 
(29%), suggesting that E l l  and E12 were poor substrates com­
pared with Phos(9-18). Because the lower enzymatic efficiencies 
were mainly due to the greater K m values, we suggest that Lys11 
(P-3 site) and Gin12 (P-2 site) in the Phos(9-18) peptide are 
crucial for optimal substrate recognition.
Mapping the Substrate Binding Sites Using Peptide Ana­
logs—Based on the crystal structure of cyclic AMP-dependent 
protein kinase-inhibitor complex (28, 29) and mutagenesis 
studies of yeast cyclic AMP-dependent protein kinase (30, 31), 
it has been concluded that Glu127 and Glu170 in cyclic AMP- 
dependent protein kinase (equivalent to Glu111 and Glu154 in y) 
are involved in the recognition of Arg residues in the P-3 and 
P-2 positions of Kemptide, respectively. Interestingly, two mu­
tant forms of y!_3oo> E111K and E154R, were shown to influ­
ence the binding of substrates (18). In the present study, we 
utilized peptide analogs (E ll  and E12) in combination with 
charge-reversal mutant of y^ oo  (E111K and E154R) to iden­
tify possible interactions between Glu111  and Glu154 in y^ oo  
and Lys11 and Gin12 in Phos(9-18) peptide.
To determine if either Glu111 or Glu154 in y^ oo  participates 
in the binding of Lys11  at the P-3 site in Phos(9-18), wild-type 
7 i_3o0 and both E111K and E154R mutants were subjected to 
kinetic analyses by using Phos(9-18) and E l l  peptides as 
substrates. If either residue Glu111  or Glu154 in y1_300 interacts 
with the residue at the P-3 site of 9 -18  peptide, it would be 
expected that charge-reversal mutations at these positions 
would negatively affect substrate kinetics and that charge re­
versal at the P-3 site in the peptide E l l  (Lys11 —» Glu) would 
reverse or attenuate these negative effects. The kinetic param­
eters and relative catalytic efficiencies calculated from these 
experiments are presented in Table II. Using wild-type y^oo* 
a 10-fold greater Km value was observed with E l l  as substrate
2 We have prepared several other Phos(9—18) peptide analogs and 
those analogs have been tested as substrates for We will describe
the effects of these analogs and the mapping results elsewhere.
than Phos(9-18). There were no significant differences in the 
Km or Vmax values of the E154R mutant using either E l l  or 
Phos(9-18) peptide. These data suggest that Glu154 in yx_300 
does not interact with the P-3 residue in the substrate. Our 
results agree with the results of the co-crystal structure of 
cyclic AMP-dependent protein kinase and PKI, which shows 
that Glu170 (or Glu154 in y) does not contact the P-3 site of PKI.
A dramatic increase in the relative efficiency of the E111K 
mutant toward E l l  (33-fold) was found. The results indicate 
that the charge reversal in y^ oo  (Glu111  —* Lys) was compen­
sated by the peptide substrate charge reversal (Lys11 —* Glu). 
We interpret these data to mean that Glu111  in y^ oo  interacts 
with Lys11 at the P-3 site of the Phos(9-18) peptide substrate.
To learn whether Glu154 interacts with the P-2 site in the 
substrate as it does with cyclic AMP-dependent protein kinase, 
the kinetics of phosphorylation of Phos(9—18) and E12 peptides 
were analyzed. Charge reversal at residue 154 in y1„3()0 (Glu154 
—» Arg) and substitution at the P-2 residue in the substrate 
peptide (Gin12 —» Glu) might be predicted to improve substrate 
kinetics if  there are interactions between residue 154 and the 
P-2 site in the substrate. The kinetic data confirmed this pre­
diction (Table II). As shown previously, in wild-type y^ oo. a 
3-fold decrease in relative enzymatic efficiency was seen using 
E12 as a substrate compared with Phos(9-18). There was no 
significant difference in relative enzymatic efficiency with 
E111K toward Phos(9-18) (0.0013) or E12 (0.0017). A greater 
relative enzymatic efficiency was seen with E154R toward E12 
peptide (0.32) than Phos(9-18) peptide (0.11). The results sup­
port the view that Glu154 interacts with the P-2 site in the 
Phos(9-18) peptide.
Inhibitory Mechanism ofPhK13—Previously we showed that 
PhK13 is a competitive inhibitor with respect to phosphorylase 
b and hence may bind directly to the substrate binding site of 
the y-subunit. To provide additional evidence that PhK13 binds 
directly to y, _300 and regulates activity via a pseudosubstrate 
mechanism, PhK13 inhibition was assayed with both the 
E111K and E154R mutants of yi_30o- Both E111K and E154R 
were inhibited competitively by PhK13 with respect to phos­
phorylase b, and the Kt values of PhK13 toward E111K and 
E154R were increased 14- and 8-fold, respectively, compared 
with wild-type y ^ o o  (Table I). Noncompetitive inhibition with 
respect to ATP with 3- and 2-fold increases in Kt values were 
found in E111K and E154R mutants, respectively (Table I). 
Because PhK5 is a noncompetitive inhibitor, we also analyzed 
the inhibition of both mutants by PhK5 to ensure that PhK13 























T a b le  III 
Recognition sites
A, the substrate and proposed pseudosubstrate (or autoinhibitory) 
regions of phosphorylase kinase are aligned based on the phosphoryl- 
atable region of phosphorylase b residues. The boxes show the phos­
phorylation and the proposed pseudosubstrate (or autoinhibitory) sites. 
When compared to Phos(9-18), the conserved residues are underlined. 
B, comparison of peptide recognition sites in 7l_300 and in cyclic AMP- 
dependent protein kinase (cAPK). The residues corresponding to Glu127 
and Glu170 in cyclic AMP-dependent protein kinase are conserved in the 
7-subunit as Glu111 and Glu154. However, Glu230 in cyclic AMP-depend­
ent protein kinase is replaced by Thr222 in the 7-subunit.
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The analyses revealed that the K t values of PhK5 toward phos­
phorylase b with either mutant were similar to that of wild­
type 7i—300 (Table I). These results suggest that neither Glu111 
nor Glu154 are involved in binding PhK5. Taking all of the data 
together, we propose that PhK13 acts as a pseudosubstrate and 
specifically binds to the phosphorylase b binding site of 7i_30o-
DISCUSSION
By using various combinations of peptide substrate analogs 
and mutants of the y-subunit (7i_3oo)> we have identified amino 
acids in the catalytic domain of the 7-subunit of phosphorylase 
kinase which recognize the substrate specificity determinants 
P-2 and P-3 of the phosphate acceptor substrate. The results 
indicate that the residues at P-3 and P-2 of the substrate (Lys11 
and Gin12, respectively) may directly interact with residues 
Glu111  and Glu154 in the active site of 7 . This result is consist­
ent with the results of cyclic AMP-dependent protein kinase 
and myosin light chain kinase (30-33) that two conserved 
glutamyl residues in the active site region play an important 
role in substrate recognition. However, Glu230 in cyclic AMP- 
dependent protein kinase, which also interacts with the P-2 
Arg of Kemptide, is replaced by Thr222 in the 7-subunit (Table 
III, part B). If the same alignment exists in these two protein 
kinases at the P-2 site, H-bonding might occur between resi­
dues in the 7-subunit, i.e. Glu154 and Thr222, and Gin12 at the 
P -2 site. Unlike Kemptide in the cyclic AMP-dependent protein 
kinase system, Arg16 at the P +2 site of Phos(9-18) was shown 
early on to be an important substrate specificity determinant 
(26, 27) for 7 . The basic residues on both sides of Ser14 in 
phosphorylase seem to be required for substrate recognition for 
phosphorylase kinase, but the basic residue at P+2 is inhibi­
tory for cyclic AMP-dependent protein kinase. This may partly 
explain why cyclic AMP-dependent protein kinase and phos­
phorylase kinase have different substrate specificity, although 
they share similar substrate recognition residues, Glu111  and 
Glu154.
The objective of the present study was to gain insight into the
structure-function relationships of phosphorylase kinase and 
its regulation. Previous studies suggested that two autoinhibi­
tory domains may exist at the C terminus of 7 , 7301-386 (ID- 
One is located before residue 331 and another after residue 
331. Two 7-subunit calmodulin-binding peptides, PhK13 (7303_ 327) and PhK5(7343_367), were tested and found to be inhibitory 
to 7i_goo- Based on the present findings, we found that the 
region 7303-327 (PhK13) functions as a pseudosubstrate autoin­
hibitory inhibitor for 7i_300 and the region 7343-367 (PhK5) acts 
as an allosteric autoinhibitory inhibitor. Both PhK13 and PhK5 
can bind calmodulin simultaneously (4); however, these two 
peptides have different structures (4), suggesting they can in­
teract with calmodulin by different ways and may have differ­
ent functions in regulating activity. It is not surprising to see 
these two peptides have different inhibitory mechanisms ob­
served here. Other studies3 (17) done using phosphorylase ki­
nase holoenzyme instead of a truncated form of the 7-subunit, 
7i_ 3oo, gave different results suggesting that other subunits of 
the enzyme can influence PhK5 and PhK13 binding events.
Like other calmodulin-dependent protein kinases, the auto­
inhibitory effect of both PhK13 and PhK5 can be released 
specifically by calmodulin (Fig. 2). It is likely that the autoin­
hibitory action of this region is regulated by calmodulin or the 
8-subunit. However, in our experiments no calcium was needed 
for good activation. This could be due to the fact that tight 
binding of calmodulin to the 7-subunit can occur in the absence 
of calcium (34). At this point, the physiological significance of 
this activation mechanism seen in vitro is not established.
Four protein kinase structures have been solved, including 
cyclic AMP-dependent protein kinase (28, 29, 35), cyclin- 
dependent kinase 2 (36), ERK2 (mitogen-activated protein ki­
nase) (37), and twitchin kinase (38). Overall, the architecture of 
these kinases is similar. Co-crystallization of cyclic AMP- 
dependent protein kinase and the tight binding competitive 
inhibitory PKI (5-24) indicates that the amino acids of PKI 
participate in binding to the active site and maintain cyclic 
AMP-dependent protein kinase in an inactive state by steric 
inhibition. The pseudosubstrate inhibition mechanism has 
been proposed for myosin light chain kinase, Ca2+/calmodulin- 
dependent protein kinase II, and protein kinase C (reviewed in 
Ref. 15). Putative structural models for these protein kinases 
have been proposed based on homolog modeling using the cyclic 
AMP-dependent protein kinase and PKI as a template (33, 
39-42). Recently, crystallization of the twitchin kinase, which 
contained the catalytic core and the autoinhibitory C-terminal 
tail, provides the direct evidence for the intrasteric mechanism 
of protein kinase regulation (38). Multicontact sites occur be­
tween the autoinhibitory tail and the active site of twitchin 
kinase. Based on the twitchin kinase crystal structure, Glu6067 
and Glu6023 in the catalytic core of twitchin kinase (equivalent 
to Glu154 and Glu111 in 7) make an electrostatic contact with its 
autoinhibitory C-terminal tail. The data support our findings 
about the important role of these two glutamyl residues in 7 
regulation.
So far, there are at least three peptides (/3420_436 (43), y328-  336 (44), and PhK13) derived from phosphorylase kinase that 
show competitive inhibition toward phosphorylase b using a 
catalytic subunit. However, there is no evidence suggesting 
there is more than one active site in the y-subunit. This raises 
another question about which sequence is a real pseudosub­
strate sequence regulating y-subunit activity. Although PhK13 
is a more potent inhibitor than (342o-436 and 7328-336> the exact 
interpretation of the inhibitory mechanisms awaits future 
structural studies of the catalytic subunit and the holoenzyme.
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